Interview with Carlos Kiffer, President, GC-2
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Address: Av. Nações Unidas, 12.399, 12º andar, cj 125 A, Edifício Landmark CEP 04578-000, São Paulo – SP,Brazil
Tel: (11) 3528 7406
Web: http://www.gcdois.com.br/
GC-2, in tune with the surge in R&D for pharmaceutical products in the region, provides intelligent solutions for this interdisciplinary scenario.
The natural growth of pharmaceuticals in the region, including herbal medicines and biotechnology products, has caused a parallel demand for project management. However, GC-2 is not just one more consulting firm. We bring the Project Management Office concept to pharmaceutical R&D.
In order to strengthen the strategic decision making process in pharmaceutical drug and product development, GC-2 offers its clients alternatives for the technical and commercial scientific monitoring of their developments:
Technical and scientific viability and patentability, Conceptualization & positioning, Structuring & management, Production and quality insurance interface, Pre-clinical pharmacological development interface, Pre-clinical toxicological development interface, Clinical development, Public agency interface, Antimicrobial development
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a…
Minister Pimentel recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
See our Cookie Privacy Policy Here